lysosomal disease

ly·so·so·mal dis·ease

a disease due to inadequate functioning of a lysosomal enzyme; most such diseases are associated with a storage disease.

ly·so·so·mal dis·ease

(lī'sō-sō'măl di-zēz')
A disease due to inadequate functioning of a lysosomal enzyme; most such diseases are associated with a storage disease.

ly·so·so·mal dis·ease

(lī'sō-sō'măl di-zēz')
Disorder due to inadequate functioning of a lysosomal enzyme.
References in periodicals archive ?
Featured News & Press Releases cover by this report include: Jan 26, 2015: Amicus Therapeutics Announces Presentations and Posters at Lysosomal Disease Network WORLD Symposium; Jan 08, 2015: Amicus Therapeutics Announces Positive Phase 3 Data on Cardiac Endpoints From Fabry Monotherapy Study 011 and Long Term Extension Study; Dec 22, 2014: Amicus Therapeutics to Present Program Updates at 33rd Annual J.
In February 2010, the company announced Phase III data at the Lysosomal Disease Network's WORLD symposium.
Shire plc (LSE: SHP, NASDAQ: SHPG), announces that the Lysosomal Disease Network (LDN) presented Shire Human Genetic Therapies (HGT) with the first ever Novel Treatment Award for VPRIV on February 14[sup.
The data were presented in an oral presentation at the Lysosomal Disease Network (LDN) World Symposium in Miami, Florida.
Raptor" or the "Company") (Nasdaq: RPTP), today announced the presentation of cystinosis data at the Annual Lysosomal Disease Network WORLD Symposium 2010, being held February 10-12 in Miami, Florida.
The results were presented for the first time this week at the Lysosomal Disease Network WORLD Symposium in Las Vegas, Nevada.
Amicus plans to provide a data update from this study at the Lysosomal Disease Network WORLD Symposium in Las Vegas, Nevada February 16-18th, 2011.
CAMBRIDGE, Massachusetts, February 3 /PRNewswire/ -- Shire plc (LSE: SHP, Nasdaq: SHPGY), the global specialty biopharmaceutical company, today announced that data from one of three Phase III clinical trials for velaglucerase alfa, the company's enzyme replacement therapy (ERT) in development for the treatment of Type 1 Gaucher disease, will be presented at the Lysosomal Disease Network (LDN) World Symposium, February 10-12, 2010 in Miami, Florida.
These data will be presented at the Annual Meeting of the Lysosomal Disease Network: WORLD Symposium 2010, February 10-12, in Miami, Florida.
NYSE-AMEX: PLX, TASE: PLX), announced today that clinical data from the switchover trial of taliglucerase alfa in patients with Gaucher disease and preclinical data on the oral enzyme glucocerebrosidase will be presented at the 7th Annual Meeting of the Lysosomal Disease Network: WORLD Symposium 2011 being held February 16-18, 2011 in Las Vegas, Nevada.
Einat Brill Almon, the Company's Senior Vice President of Product Development, will be presenting at the WORLD Symposium 2009, co-organized by Lysosomal Disease Network and the National Institutes of Health.

Full browser ?